Read Again: What is Project Revive?

Almost 400 medicines have been identified as vulnerable to shortages in England under a new risk list compiled by NHS England and Medicines UK

CREDIT: This is an edited version of an article that originally appeared in The Canary

The list highlights 378 products considered at risk because they rely on a single supplier or, in some cases, no active supplier at all, raising concerns about the resilience of the UK’s medicines supply chain. Many of the medicines included are used to treat serious and potentially life-threatening conditions, including blood clots, stroke and several forms of cancer. Around 80 of the listed drugs no longer have a manufacturer supplying the UK market, meaning that once current stock is exhausted, there may be no immediate replacement source.

Why is There a Shortage?

In some cases, manufacturers have withdrawn products because they are no longer considered commercially viable. The issue comes amid ongoing debate about medicines pricing and investment in the UK. Industry figures have argued that relatively low reimbursement levels, limited government investment and wider global market pressures have reduced the attractiveness of the UK as a launch market for innovative and established medicines alike.

In September 2025, science minister Patrick Vallance suggested that the NHS may need to pay higher prices for certain medicines to ensure pharmaceutical companies continue to supply the UK market, reflecting growing concern about long-term sustainability.

Which Medications Are Vulnerable?

Among the medicines identified as vulnerable are bendamustine, a chemotherapy treatment used in several cancers; flupentixol, prescribed for schizophrenia and other psychotic disorders; and urokinase, used in the treatment of pulmonary embolism. The list also echoes recent high-profile shortages affecting drugs such as estradiol, widely used in hormone replacement therapy; lisdexamfetamine, prescribed for ADHD; and Creon, an essential therapy for people with cystic fibrosis. These examples have already demonstrated the distress and disruption that supply instability can cause for patients and healthcare professionals.

What is Project Revive?

In response, NHS England and its partners have launched an initiative known as Project Revive. The scheme is designed to encourage manufacturers to produce or reintroduce vulnerable medicines by offering measures such as streamlined regulatory processes and fast-tracked licence approvals. The intention is to reduce barriers to market entry and make it more viable for companies to supply medicines that might otherwise be discontinued.

Project Revive will initially operate as a 12-month pilot, with plans to develop a longer-term model from 2027 if it proves effective. Those involved have expressed hope that the programme will provide greater certainty for manufacturers and strengthen the reliability of supply for NHS patients. However, while the initiative may help stabilise access to specific medicines in the short term, it does not fully address the broader structural challenges underpinning shortages, including global supply chain fragility, pricing pressures and market consolidation.

The Bigger Picture

For healthcare providers, the immediate concern is the impact on patients. News of potential shortages can generate anxiety among individuals and families who depend on consistent access to treatment, particularly for chronic or life-limiting conditions. Clear communication, reassurance about contingency planning and close liaison with pharmacy teams will be essential in maintaining trust. Project Revive represents a proactive attempt to protect the medicines pipeline, but it also highlights the need for sustained, long-term solutions to safeguard the UK’s drug supply.